{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:23:40Z","timestamp":1794349420010,"version":"4.9.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI172487"],"award-info":[{"award-number":["R01-AI172487"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R61\/R33-AI176561"],"award-info":[{"award-number":["R61\/R33-AI176561"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01-AI162242"],"award-info":[{"award-number":["P01-AI162242"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117509","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:58:51Z","timestamp":1789466331000},"page":"117509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct detection and quantification of HIV particles and their envelope trimers bound by combinations of broadly neutralizing antibodies"],"prefix":"10.1016","volume":"29","author":[{"given":"Souradip","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin T.","family":"Srivatsav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"DeVico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-7661","authenticated-orcid":false,"given":"Krishanu","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117509_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.117509_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01656-18","article-title":"Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes","volume":"93","author":"Ringe","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib3","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"Gilbert","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117509_bib4","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41467-022-34171-2","article-title":"Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity","volume":"13","author":"Ros\u00e1s-Umbert","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117509_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1133407","article-title":"Strategies to overcome HIV drug resistance-current and future perspectives","volume":"14","author":"Temereanca","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.isci.2026.117509_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-022-28307-7","article-title":"Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells","volume":"13","author":"Dufloo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117509_bib7","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117509_bib8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.str.2025.04.016","article-title":"A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV","volume":"33","author":"Sajadi","year":"2025","journal-title":"Structure"},{"key":"10.1016\/j.isci.2026.117509_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00152-22","article-title":"Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives","volume":"37","author":"Mahomed","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.isci.2026.117509_bib10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117509_bib12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117509_bib13","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1038\/s41467-024-51848-y","article-title":"Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fc\u03b3 receptors during acute SHIVAD8-EO infection","volume":"15","author":"Dias","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117509_bib14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117509_bib15","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.0505126102","article-title":"Antibody vs. HIV in a clash of evolutionary titans","volume":"102","author":"Burton","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117509_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771359","article-title":"HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model","volume":"12","author":"Siracusano","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117509_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41564-019-0392-y","article-title":"Antibody responses to viral infections: a structural perspective across three different enveloped viruses","volume":"4","author":"Murin","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.isci.2026.117509_bib18","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117509_bib19","article-title":"Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117509_bib20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/QAD.0000000000001102","article-title":"Neutralizing antibody affords comparable protection against vaginal and rectal simian\/human immunodeficiency virus challenge in macaques","volume":"30","author":"Moldt","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.isci.2026.117509_bib21","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117509_bib22","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12517","article-title":"The quest for an antibody-based HIV vaccine","volume":"275","author":"Haynes","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.117509_bib24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117509_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature13601","article-title":"Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface","volume":"515","author":"Huang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117509_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/v16060911","article-title":"The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention","volume":"16","author":"Thavarajah","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.117509_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01883-17","article-title":"Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells","volume":"92","author":"Cohen","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib29","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acsomega.2c07933","article-title":"An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1","volume":"8","author":"Kumar","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.isci.2026.117509_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44722-2","article-title":"Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana","volume":"13","author":"Moraka","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117509_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01720-23","article-title":"A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope","volume":"98","author":"Joshi","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nri3516","article-title":"Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning","volume":"13","author":"Kwong","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.117509_bib33","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117509_bib34","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104651118","article-title":"Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody","volume":"118","author":"Meijers","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117509_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh0004","article-title":"Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana","volume":"15","author":"Shapiro","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117509_bib36","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76004","article-title":"Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1","volume":"11","author":"LaMont","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.isci.2026.117509_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105788","article-title":"Next-generation bNAbs for HIV-1 cure strategies","volume":"222","author":"Schriek","year":"2024","journal-title":"Antiviral Res."},{"key":"10.1016\/j.isci.2026.117509_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12981-025-00734-8","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review","volume":"22","author":"Mahomed","year":"2025","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.isci.2026.117509_bib42","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117509_bib43","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117509_bib44","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117509_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.052","article-title":"Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition","volume":"31","author":"Gorman","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117509_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.celrep.2019.08.074","article-title":"Stoichiometric Analyses of Soluble CD4 to Native-like HIV-1 Envelope by Single-Molecule Fluorescence Spectroscopy","volume":"29","author":"Agrawal","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117509_bib47","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fimmu.2019.01512","article-title":"Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure","volume":"10","author":"Ray","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117509_bib48","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1128\/JVI.03048-13","article-title":"Antigenic properties of the HIV envelope on virions in solution","volume":"88","author":"Ray","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004772","article-title":"Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells","volume":"11","author":"Mengistu","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.117509_bib50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nsmb.2600","article-title":"Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16","volume":"20","author":"Pancera","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.isci.2026.117509_bib51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-4690-3-39","article-title":"Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120","volume":"3","author":"Binley","year":"2006","journal-title":"Retrovirology"},{"key":"10.1016\/j.isci.2026.117509_bib52","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/jvi.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib53","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1245625","article-title":"Crystal structure of a soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Julien","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117509_bib54","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1128\/jvi.66.11.6587-6600.1992","article-title":"Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation","volume":"66","author":"Li","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib55","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117509_bib56","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/JVI.02297-12","article-title":"Antigenicity and immunogenicity of transmitted\/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1","volume":"87","author":"Liao","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib57","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.immuni.2017.11.002","article-title":"HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage","volume":"47","author":"Landais","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117509_bib58","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-018-03335-4","article-title":"Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity","volume":"9","author":"Steinhardt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117509_bib59","doi-asserted-by":"crossref","first-page":"E7151","DOI":"10.1073\/pnas.1615939113","article-title":"Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop","volume":"113","author":"Wang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117509_bib60","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.27389","article-title":"Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies","volume":"6","author":"Wang","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.isci.2026.117509_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712122","article-title":"Broadly Neutralizing Antibodies for HIV-1 Prevention","volume":"12","author":"Walsh","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117509_bib62","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/aid.2015.0135","article-title":"Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C","volume":"31","author":"Cohen","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.isci.2026.117509_bib63","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.117509_bib64","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12484","article-title":"Identification and specificity of broadly neutralizing antibodies against HIV","volume":"275","author":"McCoy","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.117509_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans","volume":"9","author":"Julien","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.117509_bib67","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.immuni.2015.10.014","article-title":"Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design","volume":"43","author":"Andrabi","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117509_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115223","article-title":"Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage","volume":"44","author":"Mason","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117509_bib69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005110","article-title":"Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies","volume":"11","author":"McCoy","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.117509_bib71","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2515135518800689","article-title":"Broadly neutralizing antibodies in HIV-1 treatment and prevention","volume":"6","author":"Kumar","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"10.1016\/j.isci.2026.117509_bib72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12977-015-0207-z","article-title":"Discrete partitioning of HIV-1 Env forms revealed by viral capture","volume":"12","author":"Stieh","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.isci.2026.117509_bib73","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.80.5.2515-2528.2006","article-title":"Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1","volume":"80","author":"Moore","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib74","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1128\/JVI.77.10.5678-5684.2003","article-title":"Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions","volume":"77","author":"Binley","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib75","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/JVI.80.3.1414-1426.2006","article-title":"Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants","volume":"80","author":"Li","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib76","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1128\/JVI.76.12.6332-6343.2002","article-title":"Envelope-Dependent, Cyclophilin-Independent Effects of Glycosaminoglycans on Human Immunodeficiency Virus Type 1 Attachment and Infection","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117509_bib77","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117509_bib78","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41598-020-57491-z","article-title":"HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens","volume":"10","author":"Shen","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117509_bib79","doi-asserted-by":"crossref","first-page":"34844","DOI":"10.1021\/acsomega.5c03887","article-title":"ACE2 Receptor and Antibody Binding to SARS-CoV-2 Spikes and Virions by Single-Molecule Fluorescence","volume":"10","author":"Dasgupta","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.isci.2026.117509_bib80","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/v16030407","article-title":"Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins","volume":"16","author":"Kumar","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.117509_bib81","doi-asserted-by":"crossref","DOI":"10.1088\/0957-0233\/24\/6\/065702","article-title":"Dual channel detection of ultra low concentration of bacteria in real time by scanning FCS","volume":"24","author":"Altamore","year":"2013","journal-title":"Meas. Sci. Technol."},{"key":"10.1016\/j.isci.2026.117509_bib82","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0006-3495(02)75195-3","article-title":"Fluorescence Intensity and Lifetime Distribution Analysis: Toward Higher Accuracy in Fluorescence Fluctuation Spectroscopy","volume":"83","author":"Palo","year":"2002","journal-title":"Biophys. J."},{"key":"10.1016\/j.isci.2026.117509_bib83","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226028889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226028889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:54:59Z","timestamp":1794347699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226028889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226028889"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117509","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct detection and quantification of HIV particles and their envelope trimers bound by combinations of broadly neutralizing antibodies","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117509"}}